Cocrystal Pharma, Inc. 8-K

What Happened Cocrystal Pharma, Inc. (NASDAQ: COCP) announced on March 9, 2026 that it issued a press release updating the company’s Phase 1b norovirus challenge study. The study is evaluating the antiviral candidate CDI-988 both as a preventive (prophylactic) and as a treatment (therapeutic) for norovirus infections. The press release was furnished with the Form 8-K as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure).

Key Details

• Form 8-K filed March 9, 2026 (Items 7.01 and 9.01).
• Study: Phase 1b norovirus challenge study evaluating CDI-988 for prevention and treatment.
• Press release providing the update is furnished as Exhibit 99.1.
• Company ticker: COCP (Cocrystal Pharma, Inc.).

Why It Matters This filing confirms the company publicly disclosed progress on a clinical-stage antiviral program, which is a material development for a small biotech. Clinical updates can change investor expectations about timelines, potential regulatory milestones, partnering opportunities, and the program’s value. Retail investors should read the March 9 press release (Exhibit 99.1) for specifics on the trial status, safety/efficacy information or timelines and watch for subsequent clinical or regulatory filings for further details.